BioDelivery raises $60 million in registered direct

BioDelivery Sciences International Inc. (NASDAQ:BDSI) raised $60 million through the sale of 7.5 million shares at $8 in a registered direct offering to institutional investors. The price is a 3% discount to the company's close of $8.26 on Friday, before BioDelivery proposed to raise $60 million in the offering. An NDA for the company's Bunavail buprenorphine naloxone is under FDA review to treat opioid dependence, with a June 7 PDUFA date. Bunavail is a buprenorphine and naloxone polymer film formulated with BioDelivery's BioErodible MucoAdhesive (BEMA) transmucosal delivery system. ...